167 related articles for article (PubMed ID: 31923159)
1. Use of IL-5 Inhibitor Benralizumab as a Novel Therapy for Eosinophilic Otitis Media: Clinical Capsule and Review of Literature.
Chow K; Cosetti MK
Otol Neurotol; 2020 Feb; 41(2):e238-e240. PubMed ID: 31923159
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
Suzaki I; Kimura Y; Tanaka A; Hirano K; Ishibashi A; Mizuyoshi T; Ando I; Kitajima T; Watanabe S; Hinohira Y; Kobayashi H
Auris Nasus Larynx; 2019 Feb; 46(1):141-146. PubMed ID: 29909018
[TBL] [Abstract][Full Text] [Related]
4. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
[TBL] [Abstract][Full Text] [Related]
6. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b.
Neff BA; Voss SG; Carlson ML; O'Brien EK; Butterfield JH
Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784
[TBL] [Abstract][Full Text] [Related]
7. Improvement of Suspected Eosinophilic Otitis Media with Targeted Biologic Therapy.
Ryder CY; Zacharek MA; Welch CM
Otol Neurotol; 2023 Jun; 44(5):462-468. PubMed ID: 37026811
[TBL] [Abstract][Full Text] [Related]
8. [SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].
Sugiyama T; Yoshida S; Kikuchi S; Iino Y
Arerugi; 2022; 71(3):242-247. PubMed ID: 35569946
[TBL] [Abstract][Full Text] [Related]
9. Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report.
van der Lans RJL; van Spronsen E; Fokkens WJ; Reitsma S
Laryngoscope; 2021 Dec; 131(12):2649-2651. PubMed ID: 34216146
[TBL] [Abstract][Full Text] [Related]
10. New Insights into Eosinophilic Otitis Media.
Kanazawa H; Yoshida N; Iino Y
Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.
Iino Y; Kakizaki K; Katano H; Saigusa H; Kanegasaki S
Clin Exp Allergy; 2005 Oct; 35(10):1370-6. PubMed ID: 16238798
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with severity of eosinophilic otitis media.
Kanazawa H; Yoshida N; Yamamoto H; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Iino Y
Auris Nasus Larynx; 2014 Dec; 41(6):513-7. PubMed ID: 25199747
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Otol Neurotol; 2012 Sep; 33(7):1218-24. PubMed ID: 22825324
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of eosinophilic otitis media: a systematic review.
Chen T; Ashman PE; Bojrab DI; Johnson AP; Hong RS; Benson B; Svider PF
Acta Otolaryngol; 2021 Jun; 141(6):579-587. PubMed ID: 33825596
[TBL] [Abstract][Full Text] [Related]
15. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
Iino Y
Auris Nasus Larynx; 2023 Aug; 50(4):479-489. PubMed ID: 36528403
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
Iino Y; Sekine Y; Yoshida S; Kikuchi S
Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
[TBL] [Abstract][Full Text] [Related]
18. [Eosinophilic otitis media].
de Jong MA; Smithuis LO; Stokroos RJ
Ned Tijdschr Geneeskd; 2014; 158():A8044. PubMed ID: 25387983
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic otitis media: a new middle ear disease entity.
Iino Y
Curr Allergy Asthma Rep; 2008 Nov; 8(6):525-30. PubMed ID: 18940145
[TBL] [Abstract][Full Text] [Related]
20. Intractable otitis media - Pathogenesis and treatment of Eosinophilic otitis media (EOM) and otitis media with Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV).
Yoshida N
Auris Nasus Larynx; 2023 Apr; 50(2):171-179. PubMed ID: 35934599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
